oral 5-aminosalicyclic acid versus 6-methylprednisolone in active crohn's disease
Clicks: 196
ID: 225563
1990
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
196 views
44 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #69 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The response to 5-aminosalicylic acid (5-ASA) in active Crohn's
disease was studied in comparison to methylprednisolone in a 24 week randomized
double-blind multicentre study. Sixty-two patients were included in the
analysis. Thirty were treated with 500 mg 5-ASA qid and 32 with methylprednisolone
(starting dose 48 mg for one week, then reduced weekly to 32, 24, 20,
16 and 12 mg with maintenance at 8 mg/day for the remaining 18 weeks). Mean
age, earlier surgical intervention, localization of Crohn's disease and extraintestinal
manifestations were not different in both groups. The Crohn's disease
activity index (CDAI) and the van Hees index were not significantly different
in both treatment groups at the entrance examination (median CDAI 232 in the
5-ASA group and 220 in the methylprednisolone group). According to the
protocol, treatment was stopped due to insufficient efficacy in 73% of the patients
receiving 5-ASA and in 34% of the patients receiving methylprednisolone (x2
test P=0.0019). The area under the curve for the CDAl was significantly greater
in 5-ASA (median 170) than in methylprednisolone (P≤0.007) (68). Eleven per
cent of patients taking 5-ASA and 26% of patients taking methylprednisolone
presented relevant side effects to treatment (not significant). It is concluded from
these data that 5-ASA at the dose used in this study is not efficient in the
treatment of active Crohn's disease. Considering recent studies in ulcerative
colitis, a trial using a higher dose is indicated.
| Reference Key |
schlmerich1990canadianoral
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Jürgen Schölmerich;Harro Jenss;Franz Hartmann;Hanne Döpfer;The German 5-ASA Study Group |
| Journal | indian journal of pharmacology |
| Year | 1990 |
| DOI |
10.1155/1990/260563
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.